deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03712098

Daily Liraglutide for Nicotine Dependence (DAL)

Glucagon-like Peptide-1 Receptor Agonists as Novel Pharmacotherapies for Nicotine Dependence

Sponsor: Novo Nordisk A/S

Conditions Smoking Cessation Weight, Body
Interventions Liraglutide Placebo Smoking Cessation Counseling
Updated 15 times since 2018 Last updated: Sep 19, 2023 Started: Nov 29, 2018 Primary completion: May 25, 2022 Completion: May 25, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Smoking Cessation and Weight, Body and is currently completed. Novo Nordisk A/S leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jan 2022 · 8 months · monthly snapshot~Jan 2022 – ~Jul 2022 · 6 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Oct 2023 [monthly]

    Completed PHASE2

  5. Jul 2022 — Jul 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Jan 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. May 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  5. Apr 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Oct 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  7. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  8. Feb 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  9. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
  • Rebecca Ashare
Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations